Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 15, 1998, Pages 1985-1990

  Valli, Matthew J ^a   Schoepp, Darryle D ^a   Wright, Rebecca A ^a   Johnson, Bryan G ^a   Kingston, Ann E ^a   Tomlinson, Rosemarie ^a   Monn, James A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRROLIDINE 2, 4 DICARBOXYLIC ACID; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID DERIVATIVE; NEUROTRANSMITTER; PHENYLGLYCINE; UNCLASSIFIED DRUG;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VITRO STUDY; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

HUMANS; HYDROLYSIS; PHOSPHATIDYLINOSITOL PHOSPHATES; PROLINE; RECEPTORS, METABOTROPIC GLUTAMATE; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032483131     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00352-7     Document Type: Article

References (17)

1. 1. Collinridge, G. L.; Lester, R. A. Pharmacol. Rev. 1989, 40, 143.
2. 2. Nakanishi, S. Science 1992, 258, 597.
3. 3. Nakanishi, S.; Masu, M. Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 319.
4. 4. Hollmann M.; Heinemann S. Annu. Rev. Neurosci. 1994, 17, 31.
5. 5. Schoepp, D. D.; Conn, P. J. Trends in Pharmacol. Sci. 1993, 14, 13.
6. 6. Pin, J.-P.; Duvoisin, R. Neuropharmacol. 1995, 34, 1.
7. 7. Conn, P. J.; Pin, J.-P. Ann. Rev. Pharmacol. Toxicol. 1997, 37, 205.
8. 8. Schoepp, D. D.; Johnson, B. G.; Salhoff, C. R.; Valli, M. J.; Desai, M. A.; Burnett, J. P.; Mayne, N. G.; Monn, J. A. Neuropharmacol. 1995, 34, 843.
9. 9. Monn, J. A.; Valli, M. J.; Johnson, B. G.; Salhoff, C. R.; Wright, R. A.; Howe, T.; Bond, A.; Lodge, D.; Griffey, K; Tizzano, J. P.; Schoepp, D. D. J. Med. Chem., 1996, 39, 2990.
10. 10. Schoepp, D. D.; Johnson, B. G.; Wright, R. A.; Salhoff, C. R.; Mayne, N. G.; Wu, S.; Cockerham, S. L.; Burnett, J. P.; Belagaje, R.; Bleakman, D.; Monn, J. A. Neuropharmacol. 1997, 36, 1.
11. 11. Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C. R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L.; Griffey, K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.; Schoepp, D. D. J. Med. Chem. 1997, 40, 528.
12. 12. Wermuth, C. G.; Mann, A.; Schoenfelder, A.; Wright, R. A.; Johnson, B. G.; Burnett, J. P.; Mayne, N. G.; Schoepp, D. D. J. Med. Chem. 1996, 39, 814.
13. th Meeting of the American Chemical Society, August 25-29, 1996, Orlando, FL. Abstract MEDI 0077.
14. 1 receptors up to 1000 μM: Tuckmantel, W.; Kozikowski, A. P.; Wang, S.; Pshenichkin, S.; Wroblewski, J. Bioorg. Med. Chem. Lett. 1997, 7, 601.
15. 15. Kingston, A. E.; Burnett, J. P.; Mayne, N. G.; Lodge, D. Neuropharmacology 1995, 34, 887-894.
16. 16. Wu, S.; Wright, R. A.; Rockey, P. K.; Burgett, S. G.; Arnold, J. S.; Rosteck, P. R. Jr.; Johnson, B. G.; Schoepp, D. D.; Belagaje, R. M. Mol. Brain Res. 1998, 53, 85.
17. 17. Hayashi, Y.; Sekiyama, N.; Nakanishi, S.; Jane, D. E.; Sunter, D. C.; Birse, E. F.; Udvarhelyi, P. M.; Watkins, J. C. J. Neurosci. 1994, 14, 3370.